Drugs / GSK1362885
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01013766 | Aug → Nov 2009 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00823940 Comparator | Jan → Apr 2009 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1362885 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00823940 ↗ |
| Action | Inhibit | “GSK1362885 is a glycogen phosphorylase inhibitor” NCT00823940 ↗ |